Pembrolizumab trials for Anatomic Stage IIIA Breast Cancer AJCC v8

All Pembrolizumab trials · All Anatomic Stage IIIA Breast Cancer AJCC v8 trials

Phase breakdown

Recruiting trials studying Pembrolizumab for Anatomic Stage IIIA Breast Cancer AJCC v8

• Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
  NCT07016399 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
  NCT06324240 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 963 locations

Common questions

How many trials study Pembrolizumab for Anatomic Stage IIIA Breast Cancer AJCC v8?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.